鲁拉西酮对首发精神分裂症伴抑郁及睡眠障碍的疗效

The Efficacy of Lurasidone in the Treatment of First-episode Schizophrenia with Depression and Sleep Disorder

目的:研究鲁拉西酮对首发精神分裂症(SCH)伴抑郁及睡眠障碍的疗效。方法:选择2022年1—6月于赣州市第三人民医院治疗的60例首发SCH伴抑郁及睡眠障碍患者,按随机数字表法分为两组,各30例。对照组采用利培酮治疗,观察组采用鲁拉西酮治疗。比较两组精神症状、睡眠质量、抑郁情况、主观舒适度及不良反应。结果:治疗前两组的阳性和阴性精神症状评定量表(PANSS)、匹兹堡睡眠质量指数(PSQI)、卡尔加里精神分裂症抑郁量表(CDSS)、主观舒适度(SWN)自评量表评分比较,差异均无统计学意义(P>0.05);治疗后观察组的PANSS评分为(48.22±7.93)分、PSQI评分为(6.39±2.17)分、CDSS评分为(5.03±1.58)分,均低于对照组的(54.73±9.65)、(8.71±2.52)、(6.97±1.80)分,SWN自评量表评分为(84.96±10.73)分,高于对照组的(76.58±12.54)分,差异均有统计学意义(P<0.05)。观察组副反应量表(TESS)评分为(2.21±0.40)分,低于对照组的(3.05±0.46)分,差异有统计学意义(P<0.05)。结论:首发SCH伴抑郁及睡眠障碍患者采用鲁拉西酮治疗有利于控制精神症状,改善抑郁症状及睡眠质量,提高主观舒适度感受,减少药物不良反应,临床应用安全有效。

Objective:To study the efficacy of Lurasidone in the treatment of first-episode schizophrenia(SCH)with depression and sleep disorder.Method:A total of 60 first-episode SCH patients with depression and sleep disorder treated in Ganzhou Third People's Hospital from January to June 2022 were selected and divided into the observation group and the control group according to the random number table method,with 30 cases in each group.The control group was treated with Risperidone,while the observation group was treated with Lurasidone.The psychiatric symptoms,sleep quality,depression,subjective comfort and adverse reactions were compared between the two groups.Result:There were no significant differences in the scores of positive and negative syndrome scale(PANSS),Pittsburgh sleep quality index(PSQI),Calgary depression scale for schizophrenia(CDSS)and subjective well-being under neuroleptics(SWN)self-rating scale between the two groups before treatment(P>0.05);after treatment,the PANSS score of the observation group was(48.22±7.93)points,PSQI score was(6.39±2.17)points,CDSS score was(5.03±1.58)points,which were lower than(54.73±9.65),(8.71±2.52),(6.97±1.80)points of the control group,and the SWN self-rating scale score was(84.96±10.73)points,which was higher than(76.58±12.54)points of the control group,the differences were statistically significant(P<0.05).The score of treatment emergent symptom scale(TESS)in the observation group was(2.21±0.40)points,which was lower than(3.05±0.46)points in the control group,the difference was statistically significant(P<0.05).Conclusion:Lurasidone in the treatment of first-episode SCH patients with depression and sleep disorder is beneficial to control psychiatric symptoms,improve depressive symptoms and sleep quality,improve subjective comfort,and reduce adverse drug reactions,with safe and effective clinical application.